{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:31Z","timestamp":1791945931543,"version":"4.3.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"DOI":"10.1038\/s41571-026-01216-0","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:56:59Z","timestamp":1791925019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval"],"prefix":"10.1038","author":[{"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2605555","volume":"395","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. 395, 325\u2013337 https:\/\/doi.org\/10.1056\/NEJMoa2605555 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1216_CR2","unstructured":"US Food and Drug Administration. FDA approves first in class targeted therapy for metastatic pancreatic cancer. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer (2026)."},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","volume":"10","author":"K Choucair","year":"2025","unstructured":"Choucair, K. et al. Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. Sig. Transduct. Target. Ther. 10, 385 https:\/\/doi.org\/10.1038\/s41392-025-02473-8 (2025).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"1216_CR4","unstructured":"Incorvaia, D. As RevMed preps for \u2018historic\u2019 pancreatic cancer launch, questions linger on the ground. Fierce Pharma https:\/\/www.fiercepharma.com\/pharma\/revmed-preps-historic-pancreatic-cancer-launch-questions-linger-ground (2026)."},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"8480","DOI":"10.1002\/cam4.3477","volume":"9","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly, E. M. et al. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: treatment, sequencing, and effects on survival outcomes. Cancer Med. 9, 8480\u20138490 https:\/\/doi.org\/10.1002\/cam4.3477 (2020).","journal-title":"Cancer Med."},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/oncolo\/oyac028","volume":"27","author":"R Elias","year":"2022","unstructured":"Elias, R. et al. Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncologist 27, 469\u2013475 https:\/\/doi.org\/10.1093\/oncolo\/oyac028 (2022).","journal-title":"Oncologist"},{"key":"1216_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamasurg.2023.7872","volume":"159","author":"TM Mackay","year":"2024","unstructured":"Mackay, T. M. et al. Implementation of best practices in pancreatic cancer care in the Netherlands: a stepped-wedge randomized clinical trial. JAMA Surg. 159, 429\u2013437 https:\/\/doi.org\/10.1001\/jamasurg.2023.7872 (2024).","journal-title":"JAMA Surg."},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.annonc.2026.05.510","volume":"37","author":"T Seufferlein","year":"2026","unstructured":"Seufferlein, T. et al. 471TiP RASolute 303: a phase III global, multicenter, open-label, randomized 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel as a first line treatment for patients with metastatic pancreatic adenocarcinoma. Ann. Oncol. 37, S171 https:\/\/doi.org\/10.1016\/j.annonc.2026.05.510 (2026).","journal-title":"Ann. Oncol."},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/j.annonc.2026.05.511","volume":"37","author":"MP Ducreux","year":"2026","unstructured":"Ducreux, M. P. et al. 472TiP RASolute 304: a phase III multicenter, open-label, randomized study of adjuvant daraxonrasib versus observation following completion of neoadjuvant and\/or adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma (PDAC). Ann. Oncol. 37, S172 https:\/\/doi.org\/10.1016\/j.annonc.2026.05.511 (2026).","journal-title":"Ann. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01216-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:03:53Z","timestamp":1791943433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01216-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":9,"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01216-0","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"13 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.S. has acted as a consultant and\/or advisor of AbbVie, Astex Pharmaceuticals, AstraZeneca, Bayer, Clinical Care Communications, Daiichi Sankyo, Endeavor Biomedicines, Genmab, Illumina, Incyte, Jazz Pharmaceuticals, Lilly\/Loxo Oncology, LabGenius Therapeutics, Medscape, Med Learning Group, Novartis, Obsidian Therapeutics, OncLive, PERS, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, RevMed and Roche; and has received research funding from AbbVie, Agensys, Alfasigma, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrx, Eli Lilly\/Loxo Oncology, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche\/Genentech, Takeda, Turning Point Therapeutics and Vegenics. R.K. has acted as a consultant and\/or advisor of Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Boehringer Ingelheim, Caris, Daiichi Sankyo, Datar Cancer Genetics, EISAI, EMD Serono, EOM Pharmaceuticals, Iylon, Jackson Laboratories, LabCorp, Lanauria Therapeutics, Merck, NeoGenomics, Neomed, Nova, Novigenix, Oncoradar, Pattern, Pfizer, Precirix, Prosperdtx, Quanta Therapeutics, Recordati, Regeneron, Roche, Ryght AI, Sathgen, TD2\/Volastra, Tempus, Turning Point Therapeutics and X-Biotech; has received past or current research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Novigenix, Omniseq, Oncoradar, Pfizer, Sequenom, Sysmex, Takeda and TopAlliance; has equity interest in CureMatch; serves on advisory boards of CureMatch, CureMetrix and XZOM; and is a co-founder of CureMatch.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}